Amarin’s Challenging Outlook

Amarin’s shares rose about 22 % over the last year, yet the company’s outlook remains challenging. Its only approved product, Vascepa, has seen sales fall as generic competitors enter the market, contributing to a 6.5 % year‑over‑year decline in fiscal 2025 revenue to $213.6 million. The company has made progress cutting costs and is currently engaged in a legal dispute with Hikma Pharmaceuticals, a case that could lift its share price if resolved favorably. Amarin is shifting toward partnering with external firms for commercialization to offset its limited pipeline and dependence on a single off‑patent drug. However, the lack of additional candidates still poses a significant risk to long‑term growth. By contrast, Novartis enjoys a broader portfolio across multiple therapeutic areas, steady revenue growth, and a robust pipeline, positioning it as a more attractive investment relative to Amarin.